Nkx2.5 is one of the most widely studied cardiac-specific transcription factors, conserved from flies to man, with multiple essential roles in both the developing and adult heart. Specific dominant mutations in NKX2.5 have been identified in adult congenital heart disease patients presenting with conduction system anomalies and recent genome-wide association studies implicate the NKX2.5 locus, as causative for lethal arrhythmias ("sudden cardiac death") that occur at a frequency in the population of 1 in 1000 per annum worldwide. Haploinsufficiency for Nkx2.5 in the mouse phenocopies human conduction disease pathology yet the phenotypes, described in both mouse and man, are highly pleiotropic, implicit of unknown modifiers and/or factors acting in epistasis with Nkx2.5/NKX2.5.
T he cardiac conduction system comprises a network of specialized cardiomyocytes that generate and propagate electric impulses throughout the muscle of the heart, punctuated by nodal tissue, to collectively pace and stimulate the synchronized contraction of the atria and ventricles and facilitate unidirectional blood flow. A number of cardiac transcription factors have been implicated in the maintenance of conduction system structure and function (reviewed in Ref. 1) , of which Nkx2.5 is arguably the most well studied. However, despite a causative role for NKX2.5 in conduction disease and a substantial focus on Nkx2.5 in both the developing 2-5 and postnatal conduction system, 6 -8 there have been no reports yielding insight into upstream modifier effects on Nkx2.5 activity or physiologically relevant factors identified to rescue Nkx2.5/NKX2.5 function in disease.
The adult Nkx2.5 heterozygous mouse (Nkx2.5 Cre/ϩ ) presents with background-dependent phenotypes, including atrial septal defects and atrioventricular (AV) conduction delay, which precisely mimic the clinical symptoms in humans with pathological mutations in NKX2.5. 9 Thus the mouse, in this instance, represents a bona fide model to study the manifestation of NKX2.5-derived human adult congenital heart disease. As such we focused on candidate factors that may regulate Nkx2.5 function in this model, in the context of modifying the disease phenotype, to provide insight into pathways for potential therapeutic targeting. Prox1 is a homeobox factor we have previously shown plays a critical role in maintaining muscle structure in the developing heart. 10 Here we show that Prox1 is coexpressed with Nkx2.5 in the specialized cardiomyocytes of the conduction system and negatively regulates Nkx2.5 expression to ensure the anatomic integrity of mature atrial and ventricular conduction components, notably the atrioventricular node (AVN) and His-Purkinje network. Functional electrocardiography (ECG) parameters indicated a Prox1 mediated compensatory response to overcome PR delay indicative of AV block and chromatin immunoprecipitation (ChIP) with cotransfection reporter assays revealed Prox1 and HDAC3 as direct corepressors of Nkx2.5. These data define Prox1 as a novel modifier of Nkx2.5 function, acting in epistasis to maintain adult cardiac conduction preventing arrhythmia and conduction system disease.
Methods
An expanded Methods section is provided in the online-only Data Supplement.
Briefly, measurements of left ventricular function were attained by pressure-volume loop catheterization and micromanometry. Macroscopic examination of the internal surface of the ventricles and quantification of the number of enhanced green fluorescent protein (EGFP)ϩ cells was described previously. 7 The location of the AVN was confirmed by immunofluorescence on adjacent heart sections to those used for Picro-Sirius red staining through the AVN and its surrounding atrial and ventricular muscle; AV node size was quantified by measuring relative hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4) expression. A lead II ECG was recorded using Powerlab and Chart software v5.0 (AD Instruments, Oxford, UK) and the PR interval was calculated by averaging 2 minutes of steady state anesthetized ECGs. Cx40 BAC -GCaMP2 mice were used to obtain atrial and ventricular Ca 2ϩ transient recordings in the Purkinje fibers of the heart. Total RNA was extracted using Trizol and cDNA was synthesized using SuperscriptIII reverse transcriptase (Invitrogen). Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed using SYBR Green (Applied Biosystems) and Applied Biosystems 7900 Real-Time PCR System. Chromatin immunoprecipitation was carried out on adult hearts as described previously 10 with minor modifications. NIH3T3 and H9c2 cell culture was carried out under standard conditions and transfections were carried out using Effectene (Promega) or Lipofectamine 2000 (Invitrogen).
Results

Defects in Cardiac Function in Nkx2.5 Heterozygotes Are Rescued by Prox1 Haploinsufficiency
In our previous study we demonstrated that cardiac-specific loss-of-function of Prox1 in Nkx2.5 Cre/ϩ ;Prox1 loxP/loxP mice resulted in embryonic muscle ultrastructure defects and specifically failed maintenance of sarcomeric integrity during heart development. 10 Given the loss-of-function phenotype, we subsequently went on to examine cardiac function in Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound adult heterozygote mice to determine whether they might be compromised by loss of a single copy of Prox1. Here we used pressure-volume loop catheterization and micromanometry 11 and observed that although Nkx2.5 Cre/ϩ mice had significantly altered cardiac output there was little difference between the compound heterozygotes and the floxed-control animals (Online Table  I ). A potential caveat was that Nkx2.5 Cre/ϩ mice had significantly reduced heart rates that might be symptomatic of overanesthesia in this group leading to adverse effects on the pressure-volume relationship. However, repeat pressurevolume analyses, on 6 to 8 mice per genotype over time, revealed heart rate to be significantly lower in Nkx2.5 Cre/ϩ mice and, moreover, all functional parameters assessed including heart rate were rescued in Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ mice. This result led us to speculate that the loss of a single copy of Prox1 may rescue defects arising from Nkx2.5 haploinsufficiency. Importantly, to rule out genetic background effects as attributable to phenotypic variation, the Prox1 loxP/ϩ and Nkx2.5 Cre/ϩ parent strains were maintained on identical genetic backgrounds and the pressure-volume study and all subsequent analyses across the 3 genotypes (Prox1 loxP/ϩ , Nkx2.5 Cre/ϩ , and Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ ) were carried out on littermates within each experiment. 
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Hypoplasia of the Purkinje Fiber Network in Nkx2.5 Heterozygotes Is Rescued by Prox1 Haploinsufficiency
To investigate the potential for epistasis at a phenotypic level, we initially examined adult hearts for atrial septal and valvular defects, associated with Nkx2.5 heterozygosity (Nkx2.5 targeting generated by insertion of GFP into exon 1) 12 but failed to identify any structural anomalies of this type (not shown), presumably because of genetic background differences as previously reported. 12 In addition, we also checked for any evidence of ventricular myocardial defects and/or progressive cardiomyopathy in our Nkx2.5 Cre/ϩ mice as has been previously reported (ventricular-restricted Nkx2.5 homozygous knock-down by MLC2v Cre ) 4 alongside potential rescue in the Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound heterozygotes. No obvious myocardial defects or myopathy were observed within the ventricles of the Nkx2.5 Cre/ϩ or Nkx2.5 Cre/ϩ ; Prox1 loxP/ϩ mice at the stages (12-16 weeks of age) examined throughout this study (data not shown). Given that Nkx2.5 has also been shown to function in both the developing and adult cardiac conduction system we initially confirmed that Prox1 is expressed in cardiomyocytes of the conduction system in both the AVN and His-Purkinje fibers (PF) (Online Figure IA-ID) and subsequently sought to determine an effect of Prox1 on Nkx2.5-mediated cardiac conduction as underpinning the functional epistasis, observed from the pressure-volume micromanometry studies (Online Table I ). To visualize the His-PF network, we crossed the Prox1 loxP/ϩ and Nkx2.5 Cre/ϩ strains with a Cx40 EGFP strain. 13 Comparisons across Nkx2.5 Cre/ϩ or Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ genotypes, following crosses with Cx40 EGFP mice, were made between littermates to ensure identical genetic background. The PFs form a network of elliptical arrangements over the internal surface of the ventricles. In both the left and right ventricles, Nkx2.5 Cre/ϩ hearts displayed hypoplasia of the network demonstrated by fewer EGFPϩ fibers compared to Prox1 loxP/ϩ controls and Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound heterozygotes ( Figure 1A-1F ). To quantify the PF hypoplasia in Nkx2.5 Cre/ϩ and rescue in Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ hearts, transverse sections at 3 levels through the heart (apex, middle, and base; nϭ4 hearts per genotype) were counterstained with wheat germ agglutinin-Alexa594 to demarcate cell membranes and the number of EGFPϩ cells counted. 7 In accordance with previous studies on Nkx2.5 heterozygous mice, in which the entire Nkx2.5 coding sequence was replaced with LacZ, 7 we observed fewer EGFPϩ cells in Nkx2.5 Cre/ϩ hearts compared to controls at all 3 levels (percentage decrease: base, 50%; mid, 65%; apex, 75%), whereas in the Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound heterozygotes there was only a 30% decrease in EGFPϩ cells at all 3 levels relative to controls ( Figure 1G -1I; PՅ0.05, PՅ0.001, and PՅ0.0001 for base, mid, and apex, respectively; Figure  1J ). Furthermore, when branch points were analyzed within the His-Purkinje system there was a significant reduction in branching in the Nkx2.5 Cre/ϩ hearts relative to Prox1 loxP/ϩ control (PՅ0.005), which was rescued in the Nkx2.5 Cre/ϩ ; Prox1 loxP/ϩ compound heterozygotes (PՅ0.02; Figure 1K ). Importantly, we determined the specificity of the knock-down of Prox1 with respect to Nkx2.5 heterozygosity by examining the hearts of Mlc2v Cre/ϩ ;Prox1 loxP/ϩ mice against the respective control Prox1 loxP/ϩ and Mlc2v Cre/ϩ strains. Mlc2v Cre/ϩ mice express Cre recombinase throughout the ventricular cardiomyocytes from E8.5 onwards and also throughout the AV canal. 14 No defects were observed either in the Mlc2v Cre/ϩ or Mlc2v Cre/ϩ ;Prox1 loxP/ϩ mice at the level of the His-Purkinje conduction system (Online Figure IIA -IID), consistent with a restriction of the effects of Prox1 haploinsufficiency to the Nkx2.5 domain within the adult conduction system. This was confirmed by qRT-PCR analyses, which revealed no changes in Nkx2.5 or Cx40 (Gja5) expression between Mlc2v Cre/ϩ or Mlc2v Cre/ϩ ;Prox1 loxP/ϩ mice (Online Figure IIE ). Furthermore, a lack of phenotype in the Mlc2v Cre/ϩ ; Prox1 loxP/ϩ mice confirmed that the conduction system defects were not secondary to ventricular cardiomyocyte knock-down of Prox1 and associated ventricular dysfunction or cardiomyopathy. 10
Atrioventricular Node Hypoplasia in Nkx2.5 Heterozygotes Is Rescued by Prox1 Haploinsufficiency
An additional, well-studied, conduction system defect caused by Nkx2.5 haploinsufficiency is hypoplasia of the AVN as documented following ventricular-restricted MLC2v Cre homozygous knock-down and in animals in which Nkx2.5 was targeted by insertion of neomycin resistance cassette into intron 1 or replacement of the entire Nkx2.5 coding sequence with LacZ. 4, 5, 15 The AVN is ovoid, located between the atria and the ventricles and isolated from chamber myocardium by a fibrous tissue layer. It is responsible for the delay (pacing) between atrial and ventricular excitation allowing complete filling of the ventricles for efficient cardiac function. HCN4 is the predominant pacemaking channel expressed in the cardiac conduction system including the AVN 16 and is responsible for the hyperpolarization-activated current, I f . A combination of positive HCN4 and negative Cx40 (not shown) and Cx43 immunofluorescence (HCN4ϩ, Cx40Ϫ, Cx43Ϫ) staining 17 ( Figure 2 ) was used to precisely map the AVN within equivalent plane of heart sections across littermates of each genotype. We observed hypoplasia of the AVN and reduced expression of HCN4 in Nkx2.5 Cre/ϩ hearts compared to controls (Figure 2A -2G) whereas in compound heterozygotes the AVN was similar to controls in size (relative area as determined by Image J measurements, nϭ3; Figure 2G ), shape, and expression of HCN4 albeit with an apparent increase in myocyte density and more tightly packed collagen matrix (data not shown).
These data collectively demonstrate that the deficient AVN morphology and anatomic hypoplasia of the His-Purkinje system in Nkx2.5 heterozygotes was rescued by a corresponding reduction in Prox1 expression; which, in turn, is indicative of a role for Prox1 in regulating Nkx2.5 activity during AV pacing and the maintenance of an integral adult AV conduction system. their respective conduction system function by surface ECG. We observed a prolonged PR interval consistent with 1 stdegree AV block in the Nkx2.5 Cre/ϩ mice and individual animals with Moblitz type 1 3:2 heart block (Wenkebach; Figure 3 ) both of which have specifically been documented as progressive clinical manifestation of NKX2.5 mutations in human patients. 9 Other ECG parameters, such as QRS and QT intervals, were normal (Table) , consistent with the specificity of the NKX2.5 electrophysiological phenotype at the level of the PR interval. 9 No incidence of AV block was observed in either Prox1 loxP/ϩ control, nor Nkx2.5 Cre/ϩ ; Prox1 loxP/ϩ compound heterozygote littermates ( Figure 3A -3C). Statistical analysis across each genotype group revealed a significantly delayed PR interval (mean 0.0396 s; nϭ13; Figure 3D and Table) in the Nkx2.5 Cre/ϩ animals compared to littermate controls (mean 0.0341s; nϭ13; PՅ0.05; 1-way ANOVA) consistent with the individual examples of PR delay, AV block ( Figure 3B , 3E), and extensive hypoplasia of both the PFs and AVN (Figure 1 and 2). In accordance with functional rescue, we observed PR intervals in compound heterozygotes (mean 0.0351 s; nϭ13) that were statistically equivalent to that of control animals and significantly shortened relative to the Nkx2.5 Cre/ϩ animals ( Figure 3D ; PՅ0.05; 1-way ANOVA). Although we noted some variation in ECG parameters in control and Nkx2.5 cre/ϩ mice consistent with previous reports, 4, 12, 18 the restoration of a normal PR interval in the Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound heterozygotes suggested a Prox1-induced compensatory effect on Nkx2.5dependent electrophysiological function. Therefore, we propose that release of Prox1 inhibition of the single Nkx2.5 allele maintains the overall duration of the cardiac cycle, overriding AV block, and facilitating transmission to coordinate ventricular contraction.
Because excitation and contraction are tightly coupled, we assessed Ca 2ϩ handling in atrial and Purkinje-network myocytes, within the ventricles of Cx40 BAC -GCaMP2 mice 19 crossed onto the Nkx2.5 and Prox1 backgrounds. High speed imaging of isolated perfused mouse hearts revealed Ca 2ϩ transients in the atrium that were synchronized with transients in ventricular PFs in Prox1 loxP/ϩ control hearts ( Figure 4A ), whereas in Nkx2.5 Cre/ϩ mice Ca 2ϩ transients could be detected in the atrium but not in the ventricular myocardium ( Figure 4B ). In contrast to the mutants, Nkx2.5 Cre/ϩ ; Prox1 loxP/ϩ heterozygote animals exhibited clearly detectable PF transients of equivalent amplitude to control animals, although partially asynchronous with respect to the corresponding atrial signal ( Figure 4C ). Representative traces, as shown in Figure 4 , were supported by comparing the mean peak amplitude of PF transients, across nϭ3 mice per genotype on the Cx40 BAC -GCaMP2 background. This revealed no significant differences between Prox1 loxP/ϩ control and Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ mice (2.100Ϯ0.12 versus 1.849Ϯ0.07; nϭmean ⌬Fo/FϮSEM) but significant rescue of Ca 2ϩ handling within the ventricles of the Nkx2.5 Cre/ϩ ; Prox1 loxP/ϩ mice relative to the Nkx2.5 Cre/ϩ (1.239Ϯ0.09; PՅ0.01; 1-way ANOVA). Thus Prox1 knock-down partially restored PF Ca 2ϩ handling in line with the rescue of His-PF excitation.
Rescue of Nkx2.5 Expression and Downstream Targets and Effectors
In light of the potential for epistatic interaction between Prox1 and Nkx2.5 in the cardiac conduction system, we sought to investigate whether Prox1 might regulate Nkx2.5 gene expression. Both total RNA and protein were extracted from whole adult hearts for quantitative RT-PCR (qRT-PCR) and western blot analysis, respectively. As expected, we observed a decrease in Nkx2.5 expression in Nkx2.5 Cre/ϩ hearts and a decrease in Prox1 expression in Nkx2.5 Cre/ϩ ; Prox1 loxP/ϩ compound heterozygotes, compared to controls ( Figure 5A and Online Figure III ). However, Nkx2.5 expression in Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound heterozygotes was equivalent to control hearts, at both the RNA and protein level ( Figure 5A and Online Figure III ). This demonstrated that a reduction in Prox1 expression resulted in a concomitant increase in Nkx2.5 expression, suggesting that in the wild type situation Prox1 negatively regulates Nkx2.5 at the gene expression level.
We subsequently examined rescue of expression of downstream ion channels previously implicated as potential targets of Nkx2.5 (following tamoxifen-induced perinatal knockdown of Nkx2.5) 20 and for which specific variants (SCN5A, KCNE1, and KCNQ) have been associated with sudden cardiac death in primary arrhythmic syndromes. 21 In accordance with the earlier study, 20 qRT-PCR analyses revealed a downregulation of Scn5a, Kcne1, and Cacna1g in Nkx2.5 Cre/ϩ adult hearts; yet, in contrast, we observed an increase in Cacna1h and no change in Ryr2 ( Figure 5A ). We attribute this discrepancy to the fact that we analyzed adult heterozygote mice whereas previously the focus was exclusively on postnatal Nkx2.5-null mice. However, in line with our anatomic and functional results, we observed expression of Scn5a, Kcne1, Cacna1g, and Cacna1h return to control levels in the Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound heterozygotes (Figure 5A ). This was further supported by analyses of corresponding protein expression for Nav1.5 (Scn5a) in adult heart sections, which revealed spatial rescue of the Nav1.5 ion channel in Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound heterozygotes ( Figure  5B-5J ). The normalization of downstream effectors of Nkx2.5 function such as Kcne1 and Scn5a/Nav1.5 reflected the rescue of AV block and intraventricular conduction defects and implies that a reduction of Prox1 can rescue aberrant genetic pathways within the conduction system associated with Nkx2.5 haploinsufficiency.
Given the importance of Nkx2.5 in the developing cardiac conduction system, we investigated the expression of those 
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genes mentioned above which were significantly rescued in the adult Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound heterozygotes at E13.5; a stage consistent with functional maturation of the conduction system. 22 Interestingly, despite appropriate rescue of Nkx2.5 levels between Nkx2.5 Cre/ϩ and Nkx2.5 Cre/ϩ ; Prox1 loxP/ϩ embryos, we did not observe significant differences in expression between these 2 genotypes for Scn5a, Kcne1, or Cacna1g (Online Figure IV) . Furthermore, it has been shown previously that the peripheral conduction system develops normally in Nkx2.5 heterozygous embryos in which the entire Nkx2.5 coding sequence was replaced with LacZ. 7 Therefore, we examined E18.5 hearts from Prox1 loxP/ϩ , Nkx2.5 Cre/ϩ , and Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ genotypes (following crosses with Cx40 EGFP mice) and saw no significant difference between the 3 genotypes (Online Figure V) . Together, these results suggest that Prox1 does not regulate downstream targets of Nkx2.5 during conduction system development and that epistasis is restricted to maintenance of conduction in the adult heart.
Rescue of Generic Conduction System Genes Following Knock-Down of Prox1
In addition to known downstream targets and effectors of Nkx2.5, we determined the expression of genes that have previously been implicated as generically important for cardiac conduction. Having observed an effect on HCN4 protein expression ( Figure 2 ) we further examined all HCN pacemaker channel genes (Hcn1, Hcn2, and Hcn4) that are expressed in the heart. As predicted, from the reduced AV node HCN4 immunostaining (Figure 2A , 2C, and 2E), we observed significantly reduced Hcn4 expression in Nkx2.5 Cre/ϩ hearts, compared to controls, which was restored on the Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ background ( Figure 5K ). However, both Hcn1 and Hcn2 were increased in Nkx2.5 Cre/ϩ hearts compared to controls and further increased in Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ , with Hcn1 showing the largest fold change ( Figure 5K ). A compensatory increase in the expression of Hcn1 and Hcn2 in the rescue animals is potentially significant in that they encode HCN channels that are faster than voltage-gated variants and consequently contribute to the spontaneous rhythmic activity in the heart. 23 We next examined expression of the connexins (Cxs), which encode gap junction proteins that play a role in cardiac electric conduction and have been shown to be affected by Nkx2.5 levels. 4, 24, 25 We focused on 4 of the 5 Cxs that are expressed in the heart: Cx43 (Gja1), Cx40 (Gja5), Cx45 (Gjc1), and Cx30.2 (Gjd3), each with different expression patterns; excluding Cx30, which is expressed exclusively in the sinoatrial node, 26 anatomically and functionally upstream of the AVN and His-PF axis. Cx43 is predominantly expressed in the working cardiomyocytes of the heart and its expression was unchanged in all 3 groups ( Figure 5L ). Cx40 is strongly expressed in the atria and the ventricular conduction system and, consistent with our observed hypoplasia of the Cx40expressing His-Purkinje system and reduced endogenous Cx40 protein expression ( Figure 1 ) along with previous reports that Cx40 is reduced in Nkx2.5 heterozygotes, 18 we observed a significant decrease at the gene expression level in Nkx2.5 Cre/ϩ hearts, which was returned to normal in the Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ background ( Figure 5L ). Both Cx45 and Cx30.2 are more strongly expressed in the sinoatrial node and AVN and in line with the hypoplasia of the AVN ( Figure  2) we observed a slight decrease in expression of both genes in Nkx2.5 Cre/ϩ , relative to controls, and, in this instance, a trend toward restoration in Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ compound heterozygotes ( Figure 5L ). To investigate whether there were any effects of Prox1 on genes classically associated with the developing conduction system, we assessed a cohort of factors in adult hearts in an Nkx2.5 haploinsufficient background. We observed very little difference in the expression of Tbx2, Tbx3, Tbx5, Id2, and Irx3 between control, Nkx2.5 Cre/ϩ , and Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ hearts ( Figure 5M ). Hopx, a non-DNA binding homeobox factor thought to be downstream of Nkx2.5 during development, and which also functions in the adult conduction system, was significantly reduced in Nkx2.5 Cre/ϩ but failed to be rescued following the loss of a copy of Prox1 ( Figure 5D ). In the adult heart, Hopx functions below the AVN. Hopx-homozygous mutant mice show widening of the QRS-complex and QTinterval prolongation, 27 as such Hopx may reflect downstream function independent of the Prox1-Nkx2.5 axis. Collectively these data suggest that Nkx2.5 only regulates this cohort of factors during conduction system development and not during adulthood and is consistent with the gene expression data from E13.5 hearts (Online Figure IV) inferring a restricted role for Prox1 in maintaining the homeostatic function of the adult cardiac conduction system.
Prox1 Directly Interacts With an Upstream Nkx2.5 Enhancer
Since our anatomic, functional, and gene expression data collectively pointed to a role for Prox1 regulating Nkx2.5 in the adult conduction system, we sought to determine whether the mechanism of epistasis might be direct. We carried out in vivo ChIP experiments on adult wild type hearts using a Prox1 antibody previously used successfully for ChIP 10 and PCR detection against a well-characterized 2.1 kb enhancer For all other interval comparisons between genotypes there are no significant differences.
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sequence for Nkx2.5 located approximately 9 kb upstream of the Nkx2.5 gene. 28 The enhancer contained regulatory elements sufficient to drive transgene (lacZ or EGFP) expression in the developing heart of transgenic mice 28, 29 and when enhancer-driven EGFPϩ (Nkx2.5ϩ) derivatives were isolated by FACs, cultured, and ECG profiled, they were shown to differentiate into both contractile cardiomyocytes and conduction system cells. 29 ChIP was carried out on overlapping 100 to 300 bp fragments of the enhancer region, in line with the fact that no known consensus binding sequence for Prox1 currently exists. 10 A single fragment was enriched relative to a noantibody control and quantified by real time qPCR as 0.034% of the input chromatin ( Figure 6A-6C) ; indicative of direct Prox1 binding to the Nkx2.5 enhancer. In the absence of available Prox1-deficient adult heart tissue, as a negative control, because of the embryonic lethality of Prox1-null mutants, 10, 30 we carried out ChIP on flanking genomic fragments within the enhancer to confirm specificity of Prox1 binding to the region defined across Ϫ8943 to Ϫ9210 (Figure 6A and 6B ).
Prox1 Recruits the Transcriptional Corepressor HDAC3 to Directly Inhibit Nkx2.5 Expression
To establish how Prox1 might negatively regulate Nkx2.5 expression we carried out further ChIP and reporter-based corepression assays. Prox1 has previously been shown to act as both an activator and repressor of gene transcription. 10, 31, [31] [32] [33] [34] Repression by Prox1 was dependent on recruitment of corepressors to target promoters and one of these corepressors, HDAC3, 35, 36 has previously been implicated in regulating cardiac function. 37 We initially confirmed HDAC3 was expressed in the AVN and PF network ( Figure 6D-6G ) and to investigate whether Prox1 might act with HDAC3 to repress Nkx2.5, we determined that ␣HDAC3 immunoprecipitated the enhancer fragment, previously pulled down by Prox1, enriched to 0.141% of the input adult heart chromatin ( Figure 6A-6C) . Cotransfection experiments in NIH3T3 cells, with a luciferase reporter downstream of the full length Nkx2.5 enhancer plus a 500-bp base promoter, 29 ( Figure 6A and 6H) revealed that addition of ectopic Prox1 alone activated the enhancer-driven reporter (2.5-fold; PՅ0.01), whereas cotransfection of HDAC3 significantly repressed both nascent reporter activity (Ϫ10-fold; PՅ0.01) and that stimulated by Prox1 (Ϫ2.0-fold; PՅ0.05). Importantly, whereas the related class I HDAC protein, HDAC2, inhibited reporter activity alone, it did not inhibit Prox1-induced activation as a negative control for specificity. Addition of a Prox1 construct in which the HDAC3 interaction domain at the N-terminus was deleted 35 in combination with HDAC3, or HDAC2, failed to repress Prox1 activation of the reporter ( Figure 6H ). Treatment with Trichostatin A (10 pM), an inhibitor of class I and II HDAC activity 38 significantly enhanced reporter activation (2.5-fold relative to Prox1 plus 150 ng of HDAC3 and 10-fold relative to Prox1 plus 600 ng HDAC3; PՅ0.01 and PՅ0.001, respectively; Figure 6I ). Thus, although Prox1 alone activated the Nkx2.5 enhancer in the artificial context of single transfection and absence of cofactors, cotransfection and the recruitment of HDAC3 as a strong corepressor resulted in a net inhibition in line with a prerequisite for fine tuning of Nkx2.5 expression to ensure appropriate homeostatic conduction. To confirm that Prox1 inhibits Nkx2.5 expression, in a more physiologically relevant setting, we transfected a Prox1 siRNA into the H9c2 myogenic cell line derived from embryonic rat heart ventricle 39 and observed that endogenous levels of Nkx2.5 were significantly elevated following knock-down of Prox1 (Figure 6J and 6K). Further, siRNA experiments to knock-down HDAC3 in the same H9c2 model system confirmed a corresponding increase in Nkx2.5 expression, which was not observed for HDAC2 as a control for specificity ( Figure 6L) ; western analysis confirmed significant siRNA mediated knock-down of HDAC2 and HDAC3 protein levels (data not shown). Finally, reciprocal experiments in which we overexpressed Prox1 in H9c2 cells resulted in significant downregulation of Nkx2.5 protein as confirmed by western analysis and scanning densitometry ( Figure 6M ). Collectively, these data are consistent with Prox1 acting in conjunction with HDAC3 to directly repress Nkx2.5 in the adult conduction system.
Discussion
We identify Prox1 as an upstream modifier of Nkx2.5 function. Nkx2.5 is a conserved, critical cardiac transcription factor extensively characterized in terms of a role in cardiac morphogenesis (reviewed in Ref. 40 ) and more recently as an early commitment marker for embryonic cardiovascular progenitors. 12, 29, [41] [42] [43] In addition, its elevated expression in the developing cardiac conduction system provoked a number of studies, reviewed in Ref. 18 , including a combinatorial role with Tbx5 and Id2 in the specification of the ventricular conduction system lineage. 6 Dominant mutations in Nkx2.5 have been shown to cause congenital conduction system anomalies, most notably AV block in both mouse 4 and man, 9 and NKX2.5 was identified as a genetic determinant of PR interval and risk factor for atrial fibrillation by genome-wide association study. 44 Previous studies have highlighted Gata4 and Smad cofactors as important in the control of Nkx2.5 expression, via evolutionary conserved sites within an upstream enhancer. 28, [45] [46] [47] These studies are restricted to developmental stages and it remains unclear as to the physiological relevance of the cofactor interactions. What has not hitherto been described is epistatic rescue of Nkx2.5 biological activity during any aspect of cardiac development, function, or relevance to human disease. Genetic modifiers for Nkx2.5 were recently implied, arising from a large scale survey of Nkx2.5 heterozygous animals and, although specific variants were not identified, this study revealed extensive background-dependent buffering of Nkx2.5 haploinsufficiency underlying pleiotropic heart defects. 48 Pleiotropy also importantly holds true in humans, where patients with pathogenic NKX2.5 mutations present with atrial-septal defects but without characteristic conduction block. 49 Here we reveal how Prox1 can modulate Nkx2.5 function in the adult conduction system, such that Cremediated knock-down of Prox1 rescues conduction anomalies, arising because of Nkx2.5 haploinsufficiency, which phenocopy human NKX2.5 conduction disease. Importantly, use of congenic parent strains (Nkx2.5 Cre/ϩ and Prox1 loxP/ϩ ) and littermates for within experimental comparisons ensured the interaction of Prox1 and Nkx2.5 was not dependent on genetic background, as has previously been attributed to phenotypic variation across different lines of Nkx2.5 heterozygote mice. 12 Consequently, we excluded potential artifacts associated with unknown modifier activity. Moreover, the modulation of Nkx2.5 by Prox1 was confirmed as a primary effect at the level of the conduction system and not secondary to ventricular knock-down of Prox1 or Nkx2.5-related ventricular dysfunction and/or progressive cardiomyopathy. Multiple lines of evidence are presented to suggest that Prox1 and Nkx2.5 act in epistasis to maintain cardiac conduction. First A, B) . Prox1 and HDAC3 ChIPs were enriched relative to a no antibody control (B), confirmed by qPCR for Ct values expressed as a percentage of input (C; quantification of ChIP is shown across replicates within a single immunoprecipitation; repeat ChIP experiments nϭ3 were carried out to ensure reproducible enrichment of Prox1 and HDAC3 bound fragments, data not shown). HDAC3 immunostaining of control adult hearts revealed expression in the atrioventricular node (AVN) (D, E; white box area highlighted in D is shown at higher magnification in E; white arrowheads in E highlight HDAC3ϩ AVN cells) as determined by costaining for HCN4. In Cx40 EGFP/ϩ hearts, HDAC3 was also expressed in the EGFPϩ His-Purkinje fiber (PF) network (F, G; white box area highlighted in F is shown at higher magnification in G; white arrowheads in G highlight HDAC3ϩ PF cells). Cotransfection reporter assays in NIH3T3 cells (H) revealed that Prox1 significantly activated a luciferase reporter (A) downstream of the Nkx2.5 enhancer (compare lanes 1 and 2) whereas, both HDAC2 and HDAC3 significantly repressed reporter activity (compare lane 2 with both lanes 3 and 4). In combination, HDAC3 inhibited the Prox1 activation, whereas a similar repression was not observed with cotransfection of HDAC2 (lanes 5 and 6) as an indication of the specificity of the Prox1-HDAC3 interaction. An N-terminal deletion of Prox1 that does not interact with HDAC3 35 activated the Nkx2.5 enhancer driven reporter but was immune to repression by either HDAC2 or HDAC3 (for statistical purposes, compare lanes 6 and 9). Repeat NIH3T3 reporter transfection assays (I) revealed that HDAC3 inhibited Prox1 activation of the reporter in a dose-dependent manner (lanes 4 -6; 150 ng, 300 ng, and 600 ng HDAC3, respectively) whereas treatment with trichostatin A (TSA), a known inhibitor of histone deacetylase activity (class I and II; 38 ), restored Prox1 activation in the presence of 300 ng of HDAC3 at concentrations of 10 pM and 100 pM (lanes 8 and 9; for statistical purposes compare lanes 4 and 8; full TSA concentration range: lanes 7-10 1 pM, 10 pM, 100 pM, and 100 nM, respectively). Neither, increasing concentrations of TSA nor EtOH vehicle had any effect on basal reporter activity (lanes [11] [12] [13] [14] . Dose-dependent knock-down of Prox1 by siRNA (10 nmol/L and 15 nmol/L), in the rat ventricular cell line H9c2, resulted in significant upregulation of Nkx2.5 expression, relative to a scrambled siRNA oligo control (Co), as determined by qRT-PCR (J). Specific knock-down of Prox1 was confirmed by western analyses and scanning densitometry (K). HDAC3 siRNA-mediated knock-down resulted in a significant increase in Nkx2.5 expression in H9c2 cells, relative to a scrambled control; specificity was confirmed by the lack of effect of HDAC2 knock-down (L). Reciprocal overexpression of Prox1 in H9c2 cells resulted in a significant knock-down of Nkx2.5 protein expression compared to untransfected controls; as confirmed by western analyses in triplicate and scanning densitometry (M). *PՅ0.05, **PՅ0.01, ***PՅ0.001; Student t test. Scale bars D and F, 100 m; E and G, 20 m.
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Circulation Research July 6, 2012 functional parameters showing cardiac output deficits in Nkx2.5 heterozygotes were returned to control values following knock-down of Prox1. Second, anatomic defects in both atrial (AVN) and ventricular (His bundle branches and PFs) conduction components in Nkx2.5 heterozygous animals were significantly attenuated by a reduction in Prox1. Third, surface electrocardiograms documented evidence of AV delay with AV block in Nkx2.5 heterozygous animals, which was not only absent with Prox1 knock-down in Nkx2.5 heterozygotes but compensated for by normalized PR intervals to ensure AV conduction. Fourth, PF Ca 2ϩ transients, both duration and amplitude, were significantly restored in Nkx2.5 Cre/ϩ animals following knock-down of Prox1. Fifth, Nkx2.5 gene expression and that of a cohort of key conduction-specific genes was restored to control levels in a reduced Prox1 background relative to Nkx2.5 Cre/ϩ mutants. Finally, ChIP and siRNA loss-of-function experiments revealed Prox1 bound to a region of Nkx2.5 conduction system enhancer which, in combination with HDAC3, repressed Nkx2.5 expression and reporter gene activity.
Thus we propose a model whereby Prox1 regulates Nkx2.5 expression and activity in a stochastic manner to ensure the integrity of atrial and ventricular components and electrophysiological homeostasis in the adult heart (Figure 7) . During normal contractile function Prox1 represses Nkx2.5 to an optimal level for maintenance of adult cardiac conduction, thus avoiding compounding effects of "unconstrained" Nkx2.5 activity, as observed during development, such as myocyte hyperplasia, conduction lineage specification and morphogenetic remodeling. 6 Haploinsufficiency for Nkx2.5, although still under the inhibitory influence of Prox1, results in conduction system defects due to enforced Nkx2.5 levels below the threshold for normal anatomic and electrophysiological maintenance ( Figure 7A ). Previous reports describe that Nkx2.5 acts cell autonomously to maintain conductive phenotype in Purkinje cells and that in Nkx2.5 haploinsufficient mice conductive myocytes lose Cx40 expression and change phenotype, 7 which suggests a defect in retention of conduction system cells. Knock-down of Prox1 restores Nkx2.5 activity, in a haploinsufficient background, to a level which facilitates rescue of the morphology and function of the cardiac conduction system, potentially by maintaining appropriate levels of Cx40 expression (as shown herein) preventing conduction cell loss. The mechanism for Prox1 inhibition of Nkx2.5 appears direct, whereby Prox1 recruits the transcriptional corepressor HDAC3 to bind and negatively regulate Nkx2.5 at a proximal cardiac enhancer ( Figure  7B ). There remain some outstanding questions, including a requirement for further characterization of the Nkx2.5 conduction system enhancer we identify herein, and specifically to investigate in vivo activity within the adult conduction system. Thus far, this enhancer lies within a proximal fragment upstream of Nkx2.5, known to be active during development; however, it has also been documented to drive reporter expression within young adult hearts, active in cells that are not differentiated cardiomyocytes but have yet to be determined as components of the conduction system (Sean Wu, personal communication). The ChIP data demonstrates Figure 7 . Model of Prox1 regulation of Nkx2.5 activity in the adult cardiac conduction system. In the wild type (control) setting (Nkx2.5 ϩ/ϩ ;Prox1 loxP/ϩ ) Prox1 represses Nkx2.5 to an optimal level for maintenance of adult cardiac conduction (green solid shaded area). Haploinsufficiency for Nkx2.5 (Nkx2.5 Cre/ϩ ;Prox1 ϩ/ϩ ), although still under the inhibitory influence of Prox1, results in conduction system defects because of repressed Nkx2.5 levels below the threshold (red dashed line) for "normal" anatomic and electrophysiological maintenance (A). Knock-down of Prox1 (Nkx2.5 Cre/ϩ ;Prox1 loxP/ϩ ) restores Nkx2.5 activity, in an Nkx2.5 haploinsufficient background. Incomplete rescue, falling short of levels equivalent to that in the control animals, is subject to tolerance (dashed line and green dashed shaded region) such that rescue is still able to maintain the morphology and function of the conduction system (A). Prox1 (blue diamond) recruits the transcriptional corepressor HDAC3 (orange circle) to bind and negatively regulate Nkx2.5 at a proximal cardiac enhancer. The balance between Prox1 nascent activation and HDAC3 inhibition results in a partial net repression across both alleles in a wild type background to fine tune Nkx2.5 activity in maintaining the integrity of the AVN and His-Purkinje network and PR-interval (B, i). This level of Nkx2.5 activity is virtually recapitulated in the compound heterozygote background by the loss of Prox1, and accompanying HDAC3, at the single allele (B, ii). Whereas, in Nkx2.5 heterozygotes wild type for Prox1 repression of Nkx2.5 at the single allele enforces Nkx2.5 activity below the threshold for maintaining appropriate conduction system structure-function (B, iii).
